Arctiin protects rat heart against ischemia/reperfusion injury via a mechanism involving reduction of necroptosis
- PMID: 32135123
- DOI: 10.1016/j.ejphar.2020.173053
Arctiin protects rat heart against ischemia/reperfusion injury via a mechanism involving reduction of necroptosis
Abstract
RIPK1/RIPK3/MLKL (Receptor-interacting protein kinase 1/Receptor-interacting protein kinase 3/Mixed lineage kinase domain-like protein) pathway-mediated necroptosis contributes to myocardial ischemia/reperfusion (I/R) injury, and Arctiin can prevent myocardial fibrosis and hypertrophy. This study aims to explore the effect of Arctiin on myocardial I/R injury and the underlying mechanisms. SD rat hearts or cardiomyocytes were subjected to I/R or hypoxia/reoxygenation (H/R) to establish the I/R or H/R injury model. The methods of biochemistry, PI/DAPI (propidium iodide/4',6-Diamidino-2-Phenylindole) and H&E (Hematoxylin & eosin) staining were used to evaluate the I/R or H/R injury. The effects of Arctiin on necroptosis in I/R-treated hearts or H/R-treated cardiomyocytes were assessed. The results showed that Arctiin reduced myocardial I/R injury (decreases in myocardial infarction and creatine kinase release), concomitant with a decrease in levels of necroptosis-associated proteins (RIPK1/p-RIPK1, RIPK3/p-RIPK3 and MLKL/p-MLKL) in I/R-treated rat hearts. Consistently, the necrosis and LDH release in H/R-treated cardiomyocytes were attenuated in the presence of Arctiin, accompanied by suppression of necroptosis-relevant proteins. Furthermore, H/R-induced reactive oxygen species (ROS) generation and mitochondrial dysfunctions (increase in mitochondrial membrane potential and decrease in ATP production) were impaired by Arctiin. Using the program of the Molecular Operating Environment (MOE), we predict that RIPK1 and MLKL (but not RIPK3) might be the potential targets of Arctiin. Based on these observations, we conclude that Arctiin can protect the rat heart from I/R injury, and its beneficial effect is related to reduction of necroptosis via scavenging reactive oxygen species and restoring mitochondrial functions or targeting RIPK1 and/or MLKL.
Keywords: Arctiin; Heart; Ischemia/reperfusion; Necroptosis; RIPK.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest We declared that authors have no conflict of interest.
Similar articles
-
Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.J Cardiovasc Dev Dis. 2023 Jul 17;10(7):303. doi: 10.3390/jcdd10070303. J Cardiovasc Dev Dis. 2023. PMID: 37504559 Free PMC article. Review.
-
Inhibition of Phosphoglycerate Mutase 5 Reduces Necroptosis in Rat Hearts Following Ischemia/Reperfusion Through Suppression of Dynamin-Related Protein 1.Cardiovasc Drugs Ther. 2019 Feb;33(1):13-23. doi: 10.1007/s10557-018-06848-8. Cardiovasc Drugs Ther. 2019. PMID: 30637549
-
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1085-1095. doi: 10.1007/s00210-019-01656-9. Epub 2019 May 5. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 31055628
-
Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model.Mol Biol Rep. 2021 Mar;48(3):2507-2518. doi: 10.1007/s11033-021-06289-x. Epub 2021 Mar 23. Mol Biol Rep. 2021. PMID: 33755849
-
The role of RIPK3-regulated cell death pathways and necroptosis in the pathogenesis of cardiac ischaemia-reperfusion injury.Acta Physiol (Oxf). 2021 Feb;231(2):e13541. doi: 10.1111/apha.13541. Epub 2020 Aug 7. Acta Physiol (Oxf). 2021. PMID: 32687661 Review.
Cited by
-
Necroptosis: A Pathogenic Negotiator in Human Diseases.Int J Mol Sci. 2022 Oct 22;23(21):12714. doi: 10.3390/ijms232112714. Int J Mol Sci. 2022. PMID: 36361505 Free PMC article. Review.
-
Advances in research on the protective mechanisms of traditional Chinese medicine (TCM) in myocardial ischaemia-reperfusion injury.Pharm Biol. 2022 Dec;60(1):931-948. doi: 10.1080/13880209.2022.2063342. Pharm Biol. 2022. PMID: 35587352 Free PMC article.
-
T1AM Attenuates the Hypoxia/Reoxygenation-Induced Necroptosis of H9C2 Cardiomyocytes via RIPK1/RIPK3 Pathway.Biomed Res Int. 2022 Feb 28;2022:4833791. doi: 10.1155/2022/4833791. eCollection 2022. Biomed Res Int. 2022. PMID: 35265713 Free PMC article.
-
Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.J Cardiovasc Dev Dis. 2023 Jul 17;10(7):303. doi: 10.3390/jcdd10070303. J Cardiovasc Dev Dis. 2023. PMID: 37504559 Free PMC article. Review.
-
Decoding Parkinson's Disease: The interplay of cell death pathways, oxidative stress, and therapeutic innovations.Redox Biol. 2025 Sep;85:103787. doi: 10.1016/j.redox.2025.103787. Epub 2025 Jul 23. Redox Biol. 2025. PMID: 40712453 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous